Belantamab mafodotin extends PFS among patients with advanced multiple myeloma
Click Here to Manage Email Alerts
Belantamab mafodotin improved PFS — when combined with bortezomib and dexamethasone — as second-line treatment among patients with relapsed or refractory multiple myeloma, according to topline data from the agent’s manufacturer.
Belantamab mafodotin (Blenrep, GSK) is an antibody-drug conjugate comprised of a humanized B-cell maturation antigen monoclonal antibody conjugated to the cytotoxic agent auristatin F via a noncleavable linker.
The open-label phase 3 DREAMM-7 study assessed the efficacy and safety of belantamab mafodotin in combination with bortezomib and dexamethasone (BorDex) compared with daratumumab (Darzalex, Janssen) plus BorDex among 494 patients with relapsed or refractory multiple myeloma.
Eligible patients had documented disease progression after receiving a previous line of therapy.
Researchers randomly assigned patients in a 1:1 ratio to the investigative arm — who received 2.5 mg/kg belantamab mafodotin intravenously every 3 weeks — or the daratumumab arm.
PFS served as the primary endpoint, with key secondary endpoints including OS, duration of response and minimal residual disease negativity rate.
Researchers reported that belantamab mafodotin “significantly extended” time to disease progression or death when compared with standard of care; researchers also noted a “strong and clinically meaningful” trend in OS with a nominal P value observed.
“Patients with multiple myeloma need treatment options after first relapse that are efficacious, readily accessible and have novel mechanisms of action,” Hesham Abdullah, senior vice president of research and development at GSK, said in a press release. “We are particularly encouraged by the potential for belantamab mafodotin when combined with BorDex to address high unmet need in relapsed/refractory multiple myeloma, given the head-to-head comparison with the daratumumab-based standard-of-care regimen.”
Safety results remained consistent with the previously reported toxicity profile of belantamab mafodotin.
Detailed data from the study will be reported at an upcoming medical conference, according to the release.
Read more about
Click Here to Manage Email Alerts